Fig. 2: In vivo prophylactic and therapeutic efficacy of C12H5 in mice.
a to c Prophylactic efficacy of C12H5 against lethal challenge of MA-NC/1999 (a), MA-CA4/2009 (b), or MA-QH/2005 (c). Body weight (left) and survival (right) curves of BALB/c mice (n = 5 per group) treated with 10, 5, 2.5, or 1 mg/kg C12H5, or C12G6 (10 mg/kg) 24 h before lethal challenge are shown. d to f Therapeutic efficacy of C12H5 against lethal challenge with MA-NC/1999 (d), MA-CA4/2009 (e), and MA-QH/2005 (f). Body weight (left) and survival (right) curves of BALB/c mice (n = 5 per group) treated with 20, 10, 5, or 1 mg/kg C12H5, or C12G6 control (20 mg/kg) 24 h after lethal challenge are shown. The body weight curves in a–f reflect the weights of surviving mice; data pertaining to the mice that died after challenge were omitted from the body weight data. g Lung virus titers from mice treated with C12H5 (10 mg/kg) or C12G6 control (10 mg/kg) in the prophylactic group (n = 5 per group) were determined 6 days after infection. h Lung virus titers from mice treated with C12H5 (20 mg/kg) or C12G6 control (20 mg/kg) in the therapeutic group (n = 5 per group) were determined 6 days after infection. Data in a–h are presented as mean values ± SD. For survival data, the log-rank test was used to evaluate significance. For virus titers, each group was compared with the control group using a two-tailed Mann–Whitney U-test (***p  <  0.001; **p  <  0.01; *p  <  0.05). TCID50, median tissue culture infective dose. Source data are provided as a Source Data file.
